Multiple Myeloma News and Research RSS Feed - Multiple Myeloma News and Research

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.
Additions to standard therapy do not improve progression-free survival in patients with multiple myeloma

Additions to standard therapy do not improve progression-free survival in patients with multiple myeloma

Trial results being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone. [More]
Maintaining healthy weight may be key to prevent MGUS progression to multiple myeloma

Maintaining healthy weight may be key to prevent MGUS progression to multiple myeloma

New research shows that excess weight increases the risk that a benign blood disorder will progress into multiple myeloma, a cancer of the blood. [More]
Yale researchers develop new mouse model to understand multiple myeloma

Yale researchers develop new mouse model to understand multiple myeloma

Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale University School of Medicine. [More]
NCCN publishes new resources to help patients understand treatment options for stomach cancer

NCCN publishes new resources to help patients understand treatment options for stomach cancer

This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year. [More]
Added benefit not proven for new combination therapy in multiple myeloma

Added benefit not proven for new combination therapy in multiple myeloma

The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment. [More]
Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone. [More]
Scientists identify eight cancer types linked to excess weight and obesity

Scientists identify eight cancer types linked to excess weight and obesity

There's yet another reason to maintain a healthy weight as we age. An international team of researchers has identified eight additional types of cancer linked to excess weight and obesity: stomach, liver, gall bladder, pancreas, ovary, meningioma (a type of brain tumor), thyroid cancer and the blood cancer multiple myeloma. [More]
Socioeconomic factors may contribute to survival of young, white patients with multiple myeloma

Socioeconomic factors may contribute to survival of young, white patients with multiple myeloma

Advances in the treatment of multiple myeloma, a cancer that forms in a type of white blood cell, have led to improved survival predominantly among young and white patients, with less of an increase in survival observed in patients of other ethnicities. [More]
MGH investigators discover key molecules essential for sensing proteasome dysfunction

MGH investigators discover key molecules essential for sensing proteasome dysfunction

Maintaining appropriate levels of proteins within cells largely relies on a cellular component called the proteasome, which degrades unneeded or defective proteins to recycle the components for the eventual assembly of new proteins. [More]
FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

iCell Gene Therapeutics today (Aug. 11) announced that the Food and Drug Administration has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). [More]
Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery. [More]
New class of anti-cancer agents may be promising treatment for multiple myeloma

New class of anti-cancer agents may be promising treatment for multiple myeloma

Australian researchers have discovered that a new class of anti-cancer agents may be effective in treating multiple myeloma, an incurable bone marrow cancer. [More]

Abingdon Health declares FDA registration and CE marking of new ADxLR5 lateral flow device reader

Abingdon Health are pleased to announce the CE marking and FDA registration of their newly available immunoassay reader - ADxLR5 as a Class 1 Medical Device. [More]
Abingdon Health gains TGA regulatory approval for Seralite- FLC product in Australia

Abingdon Health gains TGA regulatory approval for Seralite- FLC product in Australia

Abingdon Health Ltd, is pleased to announce that it has gained regulatory approval by the Therapeutic Goods Administration in Australia for Seralite- FLC. [More]
Blood cancer is associated with considerably higher healthcare costs than other cancers

Blood cancer is associated with considerably higher healthcare costs than other cancers

Health economics studies, published today in The Lancet Haematology, report that the cost of treating blood cancers is twice that for treating other cancers. This is largely because they require more complex treatment regimens that necessitate longer hospital stays. [More]
New treatment approach may benefit relapsed post-transplant blood cancer patients

New treatment approach may benefit relapsed post-transplant blood cancer patients

For many patients with advanced blood cancers, a stem-cell transplant can drive the disease into remission. However, about one-third of these patients experience a relapse and face a very poor prognosis. [More]
Study shows how increase in BMI contributes to multiple myeloma growth and progression

Study shows how increase in BMI contributes to multiple myeloma growth and progression

In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
TUM researchers uncover molecular mechanism of thalidomide

TUM researchers uncover molecular mechanism of thalidomide

In the 1950s, thalidomide (Contergan) was prescribed as a sedative drug to pregnant women, resulting in a great number of infants with serious malformations. Up to now, the reasons for these disastrous birth defects have remained unclear. [More]
Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies demonstrates use of high-throughput sequencing platform for MRD

Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive’s high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry. [More]
Advertisement
Advertisement